Nearly 90 percent of newly launched medicines are available in the United States.

A 2018 analysis by U.S.-based PhRMA puts into context the current debate over drug pricing in America by highlighting the greater availability of new therapies for American patients compared to those living in other countries. While at a cost, Americans are the earliest adopters of drug technology. 

Reviewing product sales data from around the world, the analysis identified 220 new molecular entities (NMEs) launched in 36 countries from 2011 to 2017.

Of the 65 oncology NMEs identified, nearly all were available in the United States (62 medicines or 95 percent) compared to 75 percent in the United Kingdom and 51 percent in Japan. For anti-infective and anti-viral medications, 90 percent of 30 NMEs identified were available in the United States compared to 80 percent in Germany, 60 percent in France and 57 percent in Canada. Only 55 percent of the new medicines used to treat respiratory disorders were available in Canada, compared to 100 percent in the United States.

Nearly 90 percent of these newly launched medicines were available in the United States, compared to just two-thirds in the United Kingdom, half in Canada and France, and only one-third in Australia.